Compare Avient Corporation (AVNT) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avient Corporation vs McKesson Corporation — how do they compare? Avient Corporation trades at $45.51 (market cap $4.19B), while McKesson Corporation trades at $899.06 (market cap $102.58B). The key difference: McKesson Corporation is far larger — about 24.5× Avient Corporation's market cap, and Avient Corporation pays the higher dividend (2.41%). Which is the better fit depends on your goals.
| AVNT | MCK | |
|---|---|---|
Market Cap | $4.19B | $102.58B |
Sector | Technology | Health |
52-Week High | $45.69 | $995.69 |
52-Week Low | $27.48 | $659.01 |
Enterprise Value | $5.64B | $109.12B |
Dividend Yield | 2.41% | 0.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Avient Corporation (AVNT) trades at $45.69, up 7.13% with strong technical momentum. The stock shows consistent earnings beats with Q2 2026 EPS of $0.96 exceeding expectations by $0.07. Analyst consensus remains bullish with a $49.00 price target and 60% buy ratings. Recent quarterly dividend of $0.275 per share demonstrates shareholder returns while maintaining operational strength with $299M operating cash flow in 2026.
Outlook remains positive with improved full-year guidance and 20% adjusted EPS growth. Key risks include competitive pressures in chemical sector and potential margin compression. Upside potential exists toward $49-50 resistance zone, supported by strong fundamentals and institutional confidence in management's execution capabilities.
McKesson (MCK) trades at $869.58, down 0.14% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with revenue growth to $359.05B in 2025 and consistent earnings beats, including Q2 2026 EPS of $9.93 versus $9.56 expected. Valuation metrics like P/E of 23.33 and P/S of 0.26 indicate reasonable pricing relative to peers. Recent news highlights Q1 2027 results exceeding expectations and raised full-year guidance, driven by specialty drug and oncology growth.
Outlook remains positive with 80% analyst buy ratings and a $1,000 consensus price target, suggesting 15% upside. Risks include thin net margins of 1.12% and high liabilities at $76.83B, which could pressure equity during economic downturns. Investors should focus on execution of raised guidance and margin improvements from cost efficiencies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Avient Corporation
Avient Corporation is a global leader in specialized and sustainable material solutions. Formed from the legacy of PolyOne and Clariant’s masterbatch business, it provides highly engineered polymer formulations, color systems, and advanced composites that enhance the performance and sustainability of products in industries like healthcare, defense, and consumer packaging.
Read more on AVNT →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
